Lecanemab in the real world: First UK experience in the new era of disease modifying treatments for Alzheimer’s disease

Abstract

Background: Lecanemab is an anti‐amyloid monoclonal antibody demonstrated to slow cognitive decline in early Alzheimer’s disease (AD) in clinical trials. In August 2024, it was approved in the UK for the treatment of AD patients with mild cognitive impairment or early dementia who are apolipoprotein E4 heterozygotes or non‐carriers.

The paper